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1. Introduction 
The transient receptor potential vanilloid 4 (TRPV4) cation channel, a member of the TRP 
vanilloid subfamily, is expressed in a broad range of tissues, in which it contributes to the 
generation of Ca2+ signals and/or depolarization of membrane potential. TRPV4 is a 
polymodal Ca2+-permeable cation channel with a length of 871 amino acids. It shows very 
prominent outward rectification, rarely opening upon hyperpolarization. Mutational 
analyses suggest that outward rectification is governed by a gating mechanism independent 
of the main intracellular gates [1-4]. The predicted TRPV4 structure harbors six membrane-
spanning domains with a pore loop, an N-terminal domain with at least three ankyrin 
repeats, and a C-terminal domain residue within the cytoplasm [3-5]. These characters are 
common features in all six TRPVs (TRPV1–6). However, although the TRPV family shows 
similar characteristics (Fig. 1), each member has its own distinguishable functions from 
other TRPVs. 
The participation of TRPV4 in osmo and mechanotransduction is relevant to several 
important functions, including cellular and systemic volume homeostasis, arterial dilation, 
nociception, bladder voiding, and the regulation of ciliary beat frequency. TRPV4 channel 
activity can be sensitized by coapplying a variety of stimuli and by the participation of a 
number of cell signaling pathways, which suggests the presence of different regulatory sites. 
In this regard, several proteins have been proposed to modulate TRPV4 subcellular 
localization and/or function: microtubule-associated protein 7, calmodulin, F-actin, and 
pacsin3 [5, 6]. Other studies have demonstrated a functional and physical interaction 
between inositol trisphosphate receptor 3 and TRPV4, which sensitizes the latter to the 
mechano and osmotransducing messenger 5'-6'-epoxieicosatrienoic acid. TRPV4 is also 
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responsive to temperature, endogenous arachidonic acid (AA) metabolites, and phorbol 
esters, including 4-α phorbol 12, 13-didecanoate(4-αPDD), and participates in receptor-
operated Ca2+ entry; thus, showing multiple activation modes [1-7]. However, the precise 
manner in which TRPV4 is regulated in the cell by these protein interactions, chemicals, and 
stimuli remains to be clearly established.  
2. Naturally occurring TRPV4 mutants and genetic disorders 
Few naturally occurring TRPV4 mutants have been identified. Interestingly, most of these 
mis-sense and nonsense point mutations are linked with the development of genetic 
disorders in humans and a detailed list of naturally occurring TRPV4 mutations and related 
disease has been documented (Table 1 and Fig. 1). Here, I discuss some of these mutations 
that have gained importance in terms of genetic diseases [4-6]. 
2.1. Serum sodium level quantitative trait locus (hyponatremia)  
Tian et al. (2009) demonstrated that the rs3742030 single nucleotide polymorphism in the 
TRPV4 gene (P19S) is significantly associated with serum sodium concentration. After this 
discovery, hyponatremia was defined as serum sodium < 135 mEq/L in non-Hispanic 
Caucasian male populations. In heterologous expression studies in HEK293 cells, P19S 
mutant channels show a diminished response to hypotonic stress and to the 
osmotransducing lipid epoxyeicosatrienoic acid compared to that in wild-type channels. The 
P19S polymorphism affects TRPV4 function in vivo and likely influences systemic water 
balance on a population wide basis [8].  
2.2. Chronic obstructive pulmonary disease (COPD) 
COPD is characterized by airway epithelial damage, bronchoconstriction, parenchymal 
destruction, and mucus hypersecretion. Upon activation by a broad range of stimuli, TRPV4 
functions to control airway epithelial cell volume and epithelial and endothelial 
permeability; it also triggers bronchial smooth muscle contraction and participates in 
autoregulation of mucociliary transport [9, 10]. These TRPV4 functions may be important for 
regulating COPD pathogenesis; thus, TRPV4 is a candidate COPD gene. The TRPV4 P19S 
mutant, which is also characterized as the cause of hyponatremia, is observed in patients 
with COPD. 
2.3. Brachyolmia type 3 (BRAC3) [MIM:113500] 
BRAC3 has been characterized using linkage analysis and candidate gene sequencing. Rock 
et al. found that some patients affected with brachylomia have a TRPV4 missense mutation, 
specifically at positions R616Q or V620I [11]. These mutations are located in the fifth 
transmembrane region, which is part of the functional pore. Each of these two mutations 
increases basal level activity when compared to the wild-type TRPV4. Additionally, the 
response to 4-αPDD (a TRPV4 specific agonist) is greater in mutants when compared with 
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that in the wild-type [11]. This result also indicates that these two mutations preferably 
stabilize TRPV4 in its “open stage”, resulting in constitutive channel activity. BRAC3 
constitutes a clinically and genetically heterogeneous group of skeletal dysplasias 
characterized by a short trunk, scoliosis, and mild short stature. BRAC3 is an autosomal 
dominant form in which patients have severe kyphoscoliosis and flattened, irregular 
cervical vertebrae[11]. 
BRAC3, causing a R616Q gain-of-function channel, was examined and found to increase 
whole-cell current densities compared with that in wild-type channels. A single-channel 
analysis revealed that R616Q channels maintain mechanosensitivity but have greater 
constitutive activity and no change in unitary conductance or rectification [12]. BRAC3 
ranges from mild autosomal-dominant BO, diagnosed by a shortened spine with 
characteristic vertebral defects and minor defects in the long bones to metatropic dysplasia 
characterized by more prominent spine defects as well as pronounced abnormalities in the 
articular skeleton resulting in short dumbbell-shaped long bones, which leads to prenatal 
lethality in its severest form [13].  
2.4. Metatropic dysplasia (MTD) [MIM:156530] 
MTD is a clinical heterogeneous skeletal dysplasia characterized by short extremities, a short 
trunk with progressive kyphoscoliosis, and craniofacial abnormalities that include a 
prominent forehead, midface hypoplasia, and a squared-off jaw [14]. Dominant mutations in 
the gene encoding TRPV4, a calcium permeable ion channel, have been identified in all 10 of 
a series MTD cases, ranging in severity from mild to perinatal lethal [14]. MTD is also called 
metatropic dwarfism. Metatropic dysplasia is a severe spondyloepimetaphyseal dysplasia 
characterized by short limbs, enlarged joints, and usually severe kyphoscoliosis [15]. 
Radiological features include severe platyspondyly, severe metaphyseal enlargement, and 
shortening of long bones. TRPV4 I331F and P799L mutants induce MTD [16, 17]. As all the 
above mentioned mutants are naturally occurring, these mutants are not embryonically 
lethal (as most lethal mutants are naturally excluded from the population). It is also 
important to note that none of these mutants show complete loss of their prime function, i.e., 
ion conductivity [12]. 
Several experimental results suggest that some of these mutants even have enhanced 
channel opening. These results demonstrate that the lethal form of the disorder is 
dominantly inherited and suggest locus homogeneity in the disease. Furthermore, 
electrophysiological studies have shown that the mutations activate the TRPV4 channel, 
indicating that the mechanism of the disease may result from increased calcium in 
chondrocytes [12, 16, 17].  
Histological studies in two cases of lethal MTD revealed markedly disrupted endochondral 
ossification, with reduced numbers of hypertrophic chondrocytes and the presence of islands 
of cartilage within the primary mineralization zone [16]. These data suggest that altered 
chondrocyte differentiation in the growth plate leads to the clinical findings of MTD [18]. 
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2.5. Distal spinal muscular atrophy congenital non-progressive (DSMAC) 
[MIM:600175] 
DSMAC (also called hereditary motor and sensory neuropathy, Type IIC; HMSN2C) is a 
clinically variable, neuromuscular disorder characterized by a congenital lower motor 
neuron disorder restricted to the lower part of the body[19]. Clinical manifestations include 
nonprogressive muscular atrophy, thigh muscle atrophy, weak thigh adductors, weak knee 
and foot extensors, minimal jaw muscle and neck flexor weakness, flexion contractures of 
the knees and pes equinovarus. However, tendon reflexes are normal [20]. 
Inheritance is autosomal dominant. The R315W mutation has been identified in an unrelated 
family that also had HMSN2C [21]. Auer-Grumbach et al. identified two additional TRPV4 
mutations (R269H and R316C) in affected members of three additional families with these 
three phenotypes, indicating that they are allelic disorders [22]. All three mutations occurred 
at the outer helices of the ANK4 and ANK5 domains, in the N-terminal cytoplasmic domain 
(Fig. 1). In vitro functional expression studies in HeLa cells show that the mutant protein 
forms cytoplasmic aggregates and has reduced surface expression, as well as an impaired 
response to stimulus-dependent channel activity. These results suggest that the mutations 
interfere with normal channel trafficking and function [21, 22]. Furthermore, Auer-
Grumbach et al. identified a different heterozygous mutation in the TRPV4 gene (R315W; 
605427.0008) in a patient with congenital distal SMA whose other family members with the 
same mutation had phenotypes consistent with hereditary motor and sensory neuropathy-2 
or scapuloperoneal spinal muscular atrophy; thus, proving that these are allelic disorders 
with overlapping phenotypes[21, 22].  
2.6. Spondyloepiphyseal dysplasia Maroteaux type (SEDM) [MIM:184095] 
SEDM is a clinically variable spondyloepiphyseal dysplasia with manifestations limited to 
the musculoskeletal system [23]. Clinical features of SEDM include short stature, 
brachydactyly, platyspondyly, short and stubby hands and feet, epiphyseal hypoplasia of 
the large joints, and iliac hypoplasia; however, the patients have normal intelligence [23, 24]. 
Genetic mapping of patients affected with this disease show a missense mutation in TRPV4, 
either E183K, Y602C, or E797K [25]. Channel activity of the TRPV4 E797K mutant in 
HEK293 cells is constitutively active, consistent with the argument that the effects in TRPV4 
are the cause SEDM [25]. SEDM is a clinically variable spondyloepiphyseal dysplasia with 
manifestations limited to the musculoskeletal system. Clinical features include short stature, 
brachydactyly, platyspondyly, short and stubby hands and feet, epiphyseal hypoplasia of 
the large joints, and iliac hypoplasia [26]. Both SEDM and parastremmatic dysplasia are part 
of the TRPV4 dysplasia family and TRPV4 mutations show considerable variability in 
phenotypic expression resulting in distinct clinical-radiographic phenotypes.  
2.7. Parastremmatic dwarfism (PSTD) [MIM:168400]  
PSTD is also characterized by defects in TRPV4 which is a bone dysplasia characterized by 
severe dwarfism, kyphoscoliosis, distortion, and bowing of the extremities, and contractures 
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of the large joints [27]. The disease is radiographically characterized by a combination of 
decreased bone density, bowing of the long bones, platyspondyly, and striking irregularities 
of endochondral ossification with areas of calcific stippling and streaking in radiolucent 
epiphyses, metaphyses, and apophyses [27].  
In a 7-year-old girl with PSTD, Nishimura et al. (2010) analyzed the TRPV4 candidate gene 
and identified heterozygosity for a missense mutation (R594H; 605427.0003), which had 
previously been found in patients with the Kozlowski type of spondylometaphyseal 
dysplasia (SMDK; 184252)[25]. However, in patients with the Kozlowski type of 
spondylometaphyseal dysplasia (SMDK; 184252), Krakow et al. (2009) identified a 1781G-A 
transition in exon 11 of the TRPV4 gene, resulting in an arg594-to-his (R594H) substitution 
in the cytoplasmic S4 domain [12]. Thus, both PSTD and SMDK, which are caused by a 
TRPV4 mutation, seem to be associated with increased basal intracellular calcium ion 
concentration and intracellular calcium activity [12, 16, 25]. However, the Kozlowski type of 
spondylometaphyseal dysplasia (SMDK; 184252) is different from SEDM at TRPV4 
mutation sites (E183K Y602C or E797K) [23-25]. 
2.8. Charcot–Maries–Tooth disease type 2C (CMT2C) and scapuloperoneal spinal 
muscular atrophy (SPSMA) [MIM:606071]  
CMT2C is an axonal form of Charcot–Marie–Tooth disease, a disorder of the peripheral 
nervous system, characterized by progressive weakness and atrophy, initially of the 
peroneal muscles and later of the distal muscles of the arms [28]. Charcot–Marie–Tooth 
disease is classified into two main groups based on electrophysiological properties and 
histopathology: primary peripheral demyelinating neuropathies (designated CMT1 when 
they are dominantly inherited) and primary peripheral axonal neuropathies (CMT2) [29]. 
CMT2 group neuropathies are characterized by signs of axonal regeneration in the absence 
of obvious myelin alterations, normal or slightly reduced nerve conduction velocities, and 
progressive distal muscle weakness and atrophy [28, 29]. Nerve conduction velocities are 
normal or slightly reduced. CMT2C and SPSMA are also known as hereditary motor and 
sensory neuropathy type 2 (HMSN2C) [30, 31]. Patients with SPSMA are characterized by 
weakness of the scapular muscle and bone abnormalities. CMT2C leads to weakness of 
distal limbs, vocal cords, and often impairs hearing and vision [32]. Genetic analyses of 
these patients show the presence of TRPV4 missense mutations, particularly at the R269H, 
R315W, and R316C positions. [31, 33]  
2.9. Familial digital arthropathy-brachydactyly (FDAB) 
FDAB is a dominantly inherited condition that is characterized by aggressive 
osteoarthropathy of the fingers and toes and consequent shortening of the middle and distal 
phalanges [34]. Lamandé et al. showed that FDAB is caused by mutations encoding 
p.Gly270Val, p.Arg271Pro, and p.Phe273Leu substitutions in the intracellular ankyrin-repeat 
domain of the TRPV4 cation channel. The TRPV4 mutant in HEK-293 cells shows that the 
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mutant proteins have poor cell-surface localization. TRPV4 mutations that reduce channel 
activity cause a third phenotype, inherited osteoarthropathy, and show the importance of 
TRPV4 activity in articular cartilage homeostasis. Thus, the TRPV4 mutant (G270V, R271P, 
Y273L) also seems to be related with FDAB [34]. 
3. Conclusions and perspective  
The TRPV4 functional Ca2+ channel consists of homo tetramer subunits [35]. TRPV4 and 
TRPC1 can coassemble to form heteromeric TRPV4–C1 channels [36, 37]. Because the TRPV4 
ankyrin repeat is responsible for its channel selfassembly in the cell line, mutations in the 
TRPV4 ankyrin domain also seem to affect channel assembly in humans, as shown in the 
many genetic disorders (Fig. 1 and Table 1).  
 
 
 
Figure 1. The naturally mutation sites on human TRPV4. 
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Mutation Residue Change in charge Domain/m
otif 
effected 
Effects on 
ion 
conductivity 
Genetic disorder 
1 C144T (exon 2)- P19S Nonpolar to polar N-terminal Less 
conductivity 
Hyponatermia 
COPD 
2 C366T (exon 2) T89I Polar (uncharged) to 
nonpolar 
N-terminal Not done Metatropic 
dysplasia 
3 G547A (exon 3) E183K Negative to plus ARD1 Not done SEDM-PM2 
4 A590G (exon 4) K197R Plus to plus ARD2 Not done Metatropic 
dysplasia 
5 - L199F Nonpolar to aromatic ARD2 Not done Metatropic 
dysplaisa 
6 G806A (exon 5) R269H Plus to plus ARD3 Less 
conductivity 
SMA  
7 G806A (exon 5) R269H Plus to plus ARD3 More 
conductivity 
CMT2C 
8 G806A (exon 5) R269H Plus to plus ARD3 More 
conductivity 
CMT2C 
9 G806A (exon 5) R269C Plus to polar un 
charged 
ARD3 More 
conductivity 
CMT2C 
10  G270V Nonpolar to polar ARD3 Not done FDAB 
11    R271P Plus to nonpolar ARD3 Not done FDAB 
12   F273L Aromatic to nonpolar ARD3 Not done FDAB 
10 - E278K Negative to plus ARD3 Not done SMDK 
11 - T295A Polar (uncharged) to 
nonpolar 
ARD4 Not done Metatropic 
dysplaisa 
12 C943T (exon 6) R315W Plus to aromatic ARD4 Less 
conductivity 
HMSN2C 
13 C946T (exon 6) R316C Plus to polar 
(uncharged) 
ARD4 Less 
conductivity 
HMSN2C  
14 A1080T (exon 6) I331F Nonpolar to aromatic ARD5 Not done Metatropic 
dysplasia 
15 - I331T Nonpolar to polar 
(uncharged) 
ARD5 Not done Metatropic 
dysplasia 
16 A992G (exon 6) D333G Negative to nonploar ARD4 More 
conductivity 
SMDK 
17 - V342F Nonpolar to aromatic ARD5 Not done Metatropic 
dysplasia 
18 - F592L Aromatic to nonpolar TM4 Not done Metatropic 
dysplasia 
19 G1781A (exon 11) R594H Plus to plus TM4 More 
conductivity 
SMDK 
20 A1805G (exon 11) Y602C Aromatic to polar TM4-TM5 Not done SEDM-PM2 
21 C1812G (exon 11) I604M Nonpolar to nonpolar TM4-TM5 Not done Metatropic 
dyslpasia 
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Mutation Residue Change in charge Domain/m
otif 
effected 
Effects on 
ion 
conductivity 
Genetic disorder 
22 G1847A (exon 12) R616Q Plus to polar 
uncharged
TM5, pore 
region
More 
conductivity
Brachylomia 
23 C1851A (exon 12) F617L Aromatic to nonpolar TM5, pore 
region
Not done Metatropic 
dysplasia 
24 T1853C (exon 12) L618Q Nonpolar to polar 
(uncharged)
TM5, pore 
region
Not done Metatropic 
dysplasia 
25 G858A (exon 12) V620I Nonpolar to nonpolar TM5, pore 
region
More 
conductivity
Brachylomia 
26 - M625I Nonpolar to nonpolar TM5, pore 
region
Not done SMDK 
27 - L709M Nonpolar to nonpolar TM5, pore 
region
Not done SMDK  
28 C2146T (exon 13) A716S Nonpolar to polar Cytoplasm
ic side of 
TM6
Same as wild 
type 
SMDK  
29 - R775K Plus to plus C-terminal 
region
Not done Metatropic 
dysplasia 
30 - C777Y Polar (uncharged) to 
aromatic
C-terminal 
region
Not done SMDK 
31 - E797K Negative to plus C-terminal 
region
Not done SEDM-PM2 
32 - P799R Nonpolar to plus C-terminal 
region
Not done Metatropic 
dysplasia 
33 - P799S Nonpolar to polar 
(uncharged)
C-terminal 
region
Not done Metatropic 
dysplasia, 
34 - P799A Nonpolar to non polar C-terminal 
region
Not done Metatropic 
dysplasia 
35 C2396T (exon 15) P799L Nonpolar to nonpolar C-terminal Not done SMDK 
The disease abbreviation means below: 
Serum Sodium Level Quantitative Trait Locus (Hyponatermia) (the # of MIM is not available) 
Chronic obstructive pulmonary disease (COPD) (the # of MIM is not available) 
Brachyolmia type 3 (BRAC3) [MIM:113500] 
Metatropic dysplasia (MTD) [MIM:156530]; 
Distal spinal muscular atrophy congenital non-progressive (DSMAC) [MIM:600175]. (DSMAC is also called as 
Hereditary Motor and Sensory Neuropathy, Type IIC; HMSN2C)  
Spondyloepiphyseal dysplasia Maroteaux type (SEDM) [MIM:184095]. 
Parastremmatic dwarfism (PSTD) [MIM:168400]  
Charcot-Maries-Tooth disease type 2C (CMT2C) and Scapuloperoneal Spinal Muscular Atrophy (SPSMA) 
[MIM:606071]  
Familial digital arthropathy-brachydactyly (FDAB): (the # of MIM is not available) 
Kozlowski type of spondylometaphyseal dysplasia (SMDK): [mim:184252] 
*MIM : Mendelian Inheritance in Man 
Table 1. The Summary of the naturally occurring TRPV4 mutations and human diseases. 
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Our recent observations indicate that TRPV4 is modulated by phosphorylation of the Ser824 
residue as a positive regulation loop [7, 38]. However, the TRPV4 C-terminal domain near 
serine residue 824 seems to regulate its function by an unknown controlling mechanism 
beyond a phosphorylation modification, such as a protein-protein interaction with CaM. 
TRPV4 C-terminal domain mutations also seem to affect protein-protein interactions, 
resulting in the genetic disorders listed in Fig. 1 and Table 1. In the future, TRPV4 mutant 
knockdown in an animal model will be helpful to elucidate how the TRPV4 mutations cause 
the genetic disorders. 
TRPV4 was originally shown to be activated by hypotonicity, but later studies have 
demonstrated that activation can also be achieved by phorbol esters, AA, and moderate 
heat. TRPV4 appears to be an important player in pathological sensory perception and bone 
growth [1-6]. The potential effect of mutations on TRPV4 function, which are related to 
human diseases through its altered function, remains to be elucidated. Furthermore, the role 
of TRPV4 in the pathogenesis of several diseases should be characterized and how the 
channel protein contributes to the specific disease must be understood. This information 
may be useful to cure or alleviate the human diseases caused by TRPV4 
mutations.Transmembrane topology of the human TRPV4 (871aa length). Indicated are the 
three ankyrin-binding repeats (ANK; blue bar), the six trans-membrane regions (TM1–TM6), 
the Ca2 pore and the mutation site (WT; Gene Bank #. BC127052). The putative cytoplasmic 
region of N-terminal (1-471 aa) and C-terminal (718-871aa) of TRPV4 are indicated with N and 
C. Two “hot spots” in TRPV4 sequences are prominent, one at the pore region and the other 
one in the ARDs. (del: deletion, delines: deletion or insertion extra sequence, fs: fame shift) 
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